Investors & Media

Press Releases

Date Title    
Gemcabene safely lowered serum triglycerides (TGs), the primary endpoint, in a subset of FPLD patients LIVONIA, Mich. , June 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line
LIVONIA, Mich. , March 15, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening